Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Alabama at Birmingham

Sites in Birmingham, AL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:08 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1236
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Alabama at Birmingham, Birmingham, AL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Alabama at Birmingham, Birmingham, AL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 673–684 of 1,236 matching trials with a site at University of Alabama at Birmingham, Birmingham, AL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

NCT05554341
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nilotinib Hydrochloride Monohydrate, Paclitaxel
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
124
States / cities
Birmingham, Alabama • Kingman, Arizona • Palo Alto, California + 101 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 3, 2026, 5:08 AM EST
Recruiting Not applicable Interventional

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

NCT06654752
Status at this site: Recruiting
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed
Other
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
3 Years to 18 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 3, 2026, 5:08 AM EST
Active, not recruiting Phase 1 Interventional Results available

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

NCT03803774
Site status not listed — check the official record
View directory record Official record
Conditions
Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Sinonasal Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Birinapant, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 3, 2026, 5:08 AM EST
Recruiting Phase 2 Interventional

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT06547489
Status at this site: Recruiting
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Zelquistinel
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Birmingham, Alabama • Huntsville, Alabama • Encino, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 3, 2026, 5:08 AM EST
Not yet recruiting Not applicable Interventional

Optimizing Adaptive Intensive Behavioral Therapy for Obesity During the Transition to Older Adulthood

NCT07446907
Site status not listed — check the official record
View directory record Official record
Conditions
Obesity & Overweight, Sarcopenia
Interventions
High Protein Diet Counceling, Standard Protein Diet Counceling, Protein Supplement, Supervised Exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 3, 2026, 5:08 AM EST
Active, not recruiting Phase 2 Interventional Results available

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

NCT03878095
Site status not listed — check the official record
View directory record Official record
Conditions
Malignant Solid Neoplasm, Refractory Cholangiocarcinoma, Refractory Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Ceralasertib, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • New Haven, Connecticut • Trumbull, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 3, 2026, 5:08 AM EST
Recruiting Phase 2 Interventional

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

NCT06703073
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions
Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart, Cohort B: placebo, Cohort C: bevacizumab, Cohort C: placebo
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 3, 2026, 5:08 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

NCT05625659
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer
Interventions
Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)
Diagnostic Test
Lead sponsor
American College of Radiology
Other
Eligibility
45 Years to 74 Years · Female only
Enrollment
2,032 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • Boca Raton, Florida • The Villages, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 3, 2026, 5:08 AM EST
Active, not recruiting No phase listed Observational

Automated Imaging Differentiation of Parkinsonism

NCT05913687
Site status not listed — check the official record
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy
Interventions
AIDP
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
40 Years to 80 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 3, 2026, 5:08 AM EST
Recruiting Phase 3 Interventional

Multi-Center Clean Air Randomized Controlled Trial in COPD

NCT06376994
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Air cleaner, Sham air cleaner
Device
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
40 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 3, 2026, 5:08 AM EST
Active, not recruiting Phase 2 Interventional

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04557098
Site status not listed — check the official record
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Teclistamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 3, 2026, 5:08 AM EST
Active, not recruiting Phase 2 Interventional

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

NCT03237780
Site status not listed — check the official record
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography with Contrast, Eribulin Mesylate
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Buena Park, California • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 3, 2026, 5:08 AM EST

About this University of Alabama at Birmingham institution page

What this page lists
ClinicalTrials.gov records that list University of Alabama at Birmingham in Birmingham, AL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.